Recent news reveals the cure mantle cell lymphoma with stem cell transplant associated with intensive immuno-chemotherapy.

Mantle cell lymphoma (MCL) is a subset of non-Hodgkin’s lymphoma that is characterized by diffuse lymph node involvement, advanced stage of cancer at diagnosis, bone marrow involvement, and lymphoma cancer cells in the blood

Two related trials was carried out by the Researchers affiliated with the Nordic Lymphoma Group and Researchers from Emory University.

The first trial was undergone by the Researchers affiliated with the Nordic Lymphoma Group, involving 160 patients having MCL with age less than 66. They were given induction therapy with Rituxan and CHOP alternating with high-dose cytarabine. Successfully patients were then treated with BEAM (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide) or BEAC (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide). And then they were given stem cell therapy.

The result of the trial showed the overall survival of 70% and event free survival of 56%.

Second follow up trail which was done for 54 months by the Emory scientists, involving 21 MCL patients. They were treated with intensive chemotherapy followed by an autologous stem cell transplant.

The result showed overall survival of 76% with progression-free survival of 73%.

Thus concluding that stem cell transplant associated with immuno-chemotherapy can potentially cure Mantle cell Lymphoma.